Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 9/20 | 0.66 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.62 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.62 |
| ▸ | CNR2 | P34972 | 8/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.55 |
| ▸ | CASR | P41180 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1321256 | 0.88 | CNR1 (0.68) | CNR1MTNR1AMTNR1BCNR2EPHX2 | |
| SCHEMBL5468000 | 0.85 | CNR1 (0.64) | CNR1MTNR1AMTNR1BCNR2EPHX2 | |
| SCHEMBL2427167 | 0.82 | CNR1 (0.70) | CNR1MTNR1AMTNR1BCNR2EPHX2 | |
| SCHEMBL9274180 | 0.81 | ASAH1 (0.63) | CNR1MTNR1AMTNR1BCNR2EPHX2 | |
| SCHEMBL1709277 | 0.81 | MTNR1A (0.72) | CNR1MTNR1AMTNR1BCNR2EPHX2 | |
| SCHEMBL3642993 | 0.80 | MTNR1A (0.68) | CNR1MTNR1AMTNR1BCNR2EPHX2 | |
| SCHEMBL2726416 | 0.80 | MTNR1A (0.72) | CNR1MTNR1AMTNR1BCNR2EPHX2 | |
| SCHEMBL19334333 | 0.77 | CNR1 (0.55) | CNR1MTNR1AMTNR1BCNR2EPHX2 | |
| SCHEMBL30853101 | 0.77 | MTNR1A (0.64) | CNR1MTNR1AMTNR1BCNR2EPHX2 | |
| SCHEMBL663798 | 0.77 | CNR1 (0.62) | CNR1MTNR1AMTNR1BCNR2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150313898-A1 | COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-05 | — | — | US | disclosed |
| US-9073896-B2 | Compounds that inhibit human DNA ligases and methods of treating cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2015-07-07 | — | — | US | disclosed |
| US-20140113891-A1 | Compounds that inhibit human DNA ligases and methods of treating cancer | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-04-24 | — | — | US | disclosed |
| EP-1133475-A1 | SUBSTITUTED BENZO DE]ISOQUINOLINE-1,3-DIONES | MERCK PATENT GmbH (DE) | 2001-09-19 | — | — | EP | disclosed |
| WO-2000031039-A1 | SUBSTITUTED BENZO[DE]ISOQUINOLINE-1,3-DIONES | MERCK PATENT GMBH (DE) | 2000-06-02 | — | — | WO | disclosed |
| US-4933325-A | ANALGESICS, HYPOTENSIVE AGENTS | G. D. SEARLE & CO. (US) | 1990-06-12 | — | — | US | disclosed |
| US-4880829-A | ANALGESICS, HYPOTENSIVE AGENTS | G. D. SEARLE AND COMPANY (US) | 1989-11-14 | — | — | US | disclosed |
| US-4847241-A | ANALGESICS | G. D. SEARLE & CO. (US) | 1989-07-11 | — | — | US | disclosed |
| US-4822775-A | ANALGESICS | G. D. SEARLE & CO. (US) | 1989-04-18 | — | — | US | disclosed |
| EP-0215297-A2 | Substituted dipeptide amides | G.D. Searle & Co. (US) | 1987-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150313898-A1 | COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER | LIG1, LIG4, LIG3 | CNR1 4759/4885MTNR1A 4338/4885MTNR1B 4374/4885 |
| US-20140113891-A1 | Compounds that inhibit human DNA ligases and methods of treating cancer | LIG1, LIG4, LIG3 | CNR1 4759/4885MTNR1A 4338/4885MTNR1B 4374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.